Vivani Medical (NASDAQ:VANI – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.
Profitability
This table compares Vivani Medical and Aclaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivani Medical | N/A | -293.64% | -79.49% |
| Aclaris Therapeutics | -900.01% | -39.73% | -27.98% |
Analyst Ratings
This is a summary of current recommendations for Vivani Medical and Aclaris Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivani Medical | 1 | 1 | 1 | 0 | 2.00 |
| Aclaris Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Institutional and Insider Ownership
6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 46.4% of Vivani Medical shares are held by insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Vivani Medical has a beta of 3.07, indicating that its share price is 207% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
Valuation and Earnings
This table compares Vivani Medical and Aclaris Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivani Medical | N/A | N/A | -$23.49 million | ($0.45) | -3.07 |
| Aclaris Therapeutics | $18.72 million | 22.11 | -$132.07 million | ($1.38) | -2.77 |
Vivani Medical has higher earnings, but lower revenue than Aclaris Therapeutics. Vivani Medical is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aclaris Therapeutics beats Vivani Medical on 7 of the 13 factors compared between the two stocks.
About Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
